drugset / Trial / NCT02162966

Safety and Efficacy Study of High Dose Colistin

NCT02162966

Phase 4 Unknown 330 enrolled King Saud Medical City
RandomizedParallel-groupOpen-labelTreatment

Summary

Colistin is a rapidly acting bactericidal antimicrobial agent that possesses a post antibiotic effect against MDRO Gram-negative bacteria, such as as Pseudomonas aeruginosa, Acinetobacterbaumannii, and Klebsiella pneumonia.

Timeline

Start
2014-05
Primary completion
2016-10
Completion
2016-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Colistin Other / unclassified

Indications